Extracorporeal membrane oxygenation survival: External validation of current predictive scoring systems focusing on influenza A etiology. Issue 8 (19th April 2021)

• Record Type: Journal Article
• Authors: Maca, Jan; Matousek, Vojtech; Bursa, Filip; Klementova, Olga; Hanak, Roman; Burda, Michal; Sevcik, Pavel; Rulisek, Jan
• Is Part Of: Artificial organs. Volume 45:Issue 8(2021)
• Page Start: 881
• Page End: 892
• Publication Date: 2021-04-19
• Subjects: acute respiratory distress syndrome -- external validation -- extracorporeal membrane oxygenation -- influenza -- scoring system; Artificial organs -- Periodicals; 617.956
• DOI: 10.1111/aor.13932
• Languages: English
• ISSNs: 0160-564X

Abstract

Abstract: Despite increasing clinical experience with extracorporeal membrane oxygenation (ECMO), its optimal indications remain unclear. Here, we externally evaluated all currently available ECMO survival‐predicting scoring systems and the APACHE II score in subjects undergoing veno‐venous ECMO (VV ECMO) support due to acute respiratory distress syndrome (ARDS) with influenza (IVA) and non‐influenza (n‐IVA) etiologies. Our aim was to find the best scoring system for influenza A ARDS ECMO success prediction. Retrospective data were analyzed to assess the abilities of the PRESERVE, RESP, PRESET, ECMOnet, Roch, and APACHE II scores to predict patient outcome. Patients treated with veno‐venous ECMO support for ARDS were divided into two groups: IVA and n‐IVA etiologies. Parameters collected within 24 hours before ECMO initiation were used to calculate PRESERVE, RESP, PRESET, ECMOnet, Roch, and APACHE II scores. Compared to the IVA group, the n‐IVA group exhibited significantly higher ICU, 28‐day, and 6‐month mortality ( P = .043, .034, and .047, respectively). Regarding ECMO support success predictions, the area under the receiver operating characteristic curve (AUC) was 0.62 for PRESERVE, 0.44 for RESP, 0.57 for PRESET, and 0.67 for ECMOnet, and 0.62 for Roch calculated for all subjects according to the original papers. In the IVA group, APACHE II had the best predictive value for ICU, hospital, 28‐day, and 6‐month mortality (AUC values of 0.73, 0.73, 0.70, and 0.73, respectively). In the n‐IVA group, APACHE II was the best predictor of survival in the ICU and hospital (AUC 0.54 and 0.57, respectively). From all possible ECMO survival scoring systems, the APACHE II score had the best predictive value for VV ECMO subjects with ARDS caused by influenza A‐related pneumonia with a cut‐off value of about 32 points. Abstract : External validation of all ECMO survival predicting systems did not demonstrated high accuracy in our cohort of VV ECMO patients. Moreover, in more homogenous subgroup of VV‐ECMO patients suffering from influenza‐related acute respiratory failure, the best predictive value presents the APACHE II score in all types of followed mortality. The mortality rate was 18% (95% CI: 9–33%) among patients with the APACHE II score of ≤32 points versus 71% (95% CI: 30–95%) among those with a score of >32 points ( P = .001; RR, 4.02). APACHE II, Acute physiology and chronic health evaluation II; AUC, area under receiver operating curve; ECMO, extracorporeal membrane oxygenation; VV, veno‐venous.